You can buy Biganib at the lowest price at Nextgen.ooo online pharmacy. Brigatinib is an anaplastic lymphoma kinase inhibitor used to treat metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It exhibits selectivity against mutant forms of EGFR compared to the wild type. It also exhibits selectivity against 9 different crizotinib-resistant mutants of the EML4-ALK fusion gene, which plays a key role in the transformation of susceptible lung parenchyma.
 
Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and approved by the FDA on April 28, 2017. Anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer (ALK+ NSCLC) accounts for only 3-5% of NSCLC cases, but ALK mutation, overexpression, and presence in several oncogenic fusion proteins in solid and hematological tumors highlight its importance and potential as a target for cancer therapy. ALK+ NSCLC are associated with the presence of the EML4-ALK fusion gene, which is formed by the fusion of ALK with the ELM4 (echinoderm microtubule-associated protein like-4) protein, whose primary function is to properly form microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes enhanced cell growth, proliferation, and survival. The presence of mutations in the ALK kinase domain causes resistance to treatment with crizotinib. Thus, brigatinib is indicated for the treatment of patients with metastatic or locally advanced ALK-positive non-small cell lung cancer as a first-line treatment or in patients with disease progression following treatment with crizotinib.